The Drugs Controller General of India has approved Itolizumab for restricted emergency use on COVID-19 patients with moderate to severe acute respiratory distress syndrome.<br />'' <br />''Drugs Controller General of India has approved Itolizumab injection for the treatment of 'cytokine' release syndrome in moderate to severe acute respiratory distress syndrome in patients due to COVID-19. After satisfactory result from clinical trials, the drug was approved.<br />'' <br />''<span style="color: #222222;">Itolizumab injection is already an approved drug of Biocon Limited used for the treatment of patients with active moderate to severe psoriasis.</span><br />